VRTX up +2.15% percent Today $VRTX High is at 114.50 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
VRTX up +2.15% percent Today $VRTX High is at 114.50 and the Low 111.00 with current volume of 248,754.

Recent News posted below.

Vertex Pharmaceuticals Inc VRTX other info.
http://investorshangout.com/Vertex-Pharmaceut...RTX-55841/

VRTX Vertex Pharmaceuticals Inc Recent Headline News

Cystic Fibrosis Foundation Royalty Sale Will Be Transformational for People with CF
PR Newswire - 1 hr 51 mins ago
The Cystic Fibrosis Foundation announced today that its nonprofit affiliate, Cystic Fibrosis Foundation Therapeutics, has sold its royalty rights for CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation sold the rights to Royalty Pharma for $3.3 billion.
VRTX: 115.12 (+4.08)

Earnings Look Back: Vertex Pharmaceuticals Is Down 2.4% Since Reporting Quarterly Results 2 Weeks Ago (VRTX)
Comtex SmarTrend(R) - Mon Nov 17, 4:06PM CST
When Vertex Pharmaceuticals (NASDAQ:VRTX) reported earnings 20 days ago on October 28th, 2014, analysts, on average, expected the company to report a loss of $0.44 on sales of $147.5 million. Vertex Pharmaceuticals actually reported a loss of $0.37 per share on sales of $179.0 million, beating EPS estimates by $0.07 and beating revenue estimates by $31.5 million. Shares of Vertex Pharmaceuticals have slipped from $114.07 to $111.34, representing a loss of 2.4%, since the company reported earnings 20 days ago.
VRTX: 115.12 (+4.08)

Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.72 (+0.09), HAS: 56.16 (+0.04), BIIB: 304.05 (-1.51), VRTX: 115.12 (+4.08), HAL: 47.83 (-0.71), M: 61.79 (+0.34), WMT: 84.48 (+0.69), SLB: 94.06 (-1.22), COG: 33.85 (+0.58), GILD: 101.55 (-2.16), EOG: 97.00 (-0.67), ALXN: 191.86 (-0.51), MRO: 32.08 (+0.02), CSCO: 26.31 (-0.28), BHI: 62.72 (-0.83)

Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 1.22% Sell Off
Comtex SmarTrend(R) - Fri Nov 14, 4:25PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $110.05 to a high of $114.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $111.85 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 115.12 (+4.08)

Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST

BIIB: 304.05 (-1.51), VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), ALXN: 191.86 (-0.51), AMGN: 161.71 (-0.53), IBB: 294.30 (-0.95), REGN: 413.59 (+0.37), CELG: 106.36 (-0.42)

Vertex Pharmaceuticals Shares Up 21.7% Since SmarTrend's Buy Recommendation (VRTX)
Comtex SmarTrend(R) - Wed Nov 12, 5:00PM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 21.71% as of today's recent price of $116.68.
VRTX: 115.12 (+4.08)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), ACHN: 13.13 (-0.18), DNDN: 0.13 (-0.02), AMGN: 161.71 (-0.53), ABBV: 65.82 (-0.23), REGN: 413.59 (+0.37)

Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST

VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), MRK: 59.38 (-0.51), DNDN: 0.13 (-0.02), AZN: 74.38 (+0.40), TEVA: 57.38 (+0.15), ABBV: 65.82 (-0.23), GSK: 45.97 (-0.31), BMY: 58.67 (-0.03), NVS: 95.28 (-0.30)

Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.15 (-0.01), BIIB: 304.05 (-1.51), VRTX: 115.12 (+4.08), AFFX: 9.00 (-0.58)

Look for Shares of Vertex Pharmaceuticals to Potentially Pullback after Yesterday's 5.11% Rise
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.12 (+4.08)

SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 5.11% Gain
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.12 (+4.08)

Vertex Pharmaceuticals Shares Up 17.2% Since SmarTrend's Buy Recommendation (VRTX)
Comtex SmarTrend(R) - Wed Nov 05, 11:07AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 17.23% as of today's recent price of $112.39.
VRTX: 115.12 (+4.08)

Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 85.16 (-3.64), VRTX: 115.12 (+4.08), BMRN: 85.14 (-0.31), GILD: 101.55 (-2.16), ALXN: 191.86 (-0.51)

Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.12 (+4.08), GERN: 3.15 (-0.02), AMGN: 161.71 (-0.53), ABBV: 65.81 (-0.24), AEGR: 20.78 (+0.29), SNY: 47.97 (-0.39), REGN: 413.59 (+0.37)

Vertex files marketing apps for CF combo
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:55AM CST

VRTX: 115.12 (+4.08)

Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Business Wire - Wed Nov 05, 6:02AM CST
---Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation-
VRTX: 115.12 (+4.08)

5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 108.27 (-0.56), VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), MRK: 59.38 (-0.51), ABBV: 65.80 (-0.25)

Vertex to Present at the Credit Suisse Healthcare Conference on November 11
Business Wire - Thu Oct 30, 3:02PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET.
VRTX: 115.12 (+4.08)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 257

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 15

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 138

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 46

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 297

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 0

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 25

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 26

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading

Top 5 Most Recently Viewed Articles

Enhanced Insurance Solutions for Virginians Amid Rising Costs

Updated Category News Views 130

Understanding the Rising Costs of Bodily Injury Claims Bodily injury costs in Virginia are on the rise, impacting the financial health of many residents. Unforeseen incidents, from car accidents to dog bites, can swiftly escalate into significant financial burdens. Reports indicate that liability claims have surged, with the average payout increasing significantly since...

Continue Reading
Investors Notify: Class Action Suit Against Lockheed Martin

Updated Category News Views 245

Overview of the Class Action Lawsuit Bragar Eagel & Squire, P.C. has recently announced the initiation of a class action lawsuit against Lockheed Martin Corporation (NASDAQ: LMT). This lawsuit is intended for all individuals and entities that acquired Lockheed Martin securities during the designated class period, which spans from January 23, 2024, to July 21, 2025. The...

Continue Reading
Market Trends Lead MUJ Stock to New Yearly Low of $10.97

Updated Category News Views 186

Understanding the Decline of MUJ Stock In a challenging economic landscape, BlackRock's MuniHoldings New Jersey Quality Fund (MUJ) stock has faced significant declines, recently hitting a 52-week low of $10.97. This shift in value reflects broader market trends affecting municipal bond funds and investor sentiment towards interest rates and credit risk. Key Indicators Of...

Continue Reading
Public Service Company of New Mexico Announces Q1 Dividend

Updated Category News Views 92

Public Service Company of New Mexico Announces Quarterly Dividend The Board of Directors at Public Service Company of New Mexico, part of TXNM Energy (NYSE: TXNM), has officially declared its regular quarterly dividend. This announcement marks a continued commitment to returning value to shareholders. The declared dividend stands at $1.145 per share, attributed to the...

Continue Reading
Nations Photo Lab Earns Recognition for Premium Photo Services

Updated Category News Views 437

Nations Photo Lab Recognized for Outstanding Photo Services In an exciting development within the photo printing sector, Nations Photo Lab has been acknowledged as a leading provider of premium photo printing and framing services. This recognition highlights the increasing demand for unique and high-quality wall art in both residential and commercial spaces. The rise of...

Continue Reading